Jazz Pharmaceuticals plc (JAZZ)
POSITIVEFundamental
73
Price
$257.77
Market Cap
$16.32B
Part 1 · What the company is worth
Overview
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$4.60B
Trailing 12 months (through 6/30/2026)
Net Income
$941M
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$1.30B
Total Equity
$4.32B
Total Liabilities
$7.34B
Current Ratio
1.78
Interest Coverage
-
Debt/EBITDA
-
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$257.55
Current Price
$257.77
Margin of Safety
-0.1%
Fair Value Range
$167.41 - $347.69
Estimation Methods
Valuation Metrics
P/E Ratio
17.39
ROE
-8.2%
P/B Ratio
3.44
P/FCF
10.38
Gross Margin
-
ROIC
8.0%
Profitability Radar
Value Creation (Economic Moat)
ROIC
8.0%
WACC
6.3%
ROIC − WACC
+1.7 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
Fundamental Analysis Criteria
Passed (17)
- Price CAGR 8.84%
- ROIC 8.0%
- P/FCF 10.38
- Debt/Equity ratio
- Operating Margin 19.5%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Return on Tangible Assets
- ROE 21.4%
- Revenue Growth 5Y 12.5%
- Analyst Consensus 92% Buy
- Earnings Surprise avg 15.3%
- Earnings Quality (OCF/NI) 1.77
- Share Dilution -5.8%
- Net Margin Trend 20.4% vs -9.9%
- Piotroski F-Score 5/9
Failed (5)
- EPS shows upward trend
- P/B Ratio 3.44
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
Unavailable (5)
- Gross Margin NaN%
- Dividend Payout NaN%
- Interest Coverage
- Debt/EBITDA
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Mixed signals: some areas need attention
Earnings Quality
High quality: earnings backed by cash
Share Dilution
Buying back shares. Shareholder friendly
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. Bruce C. Cozadd | Co-Founder & Chairman | 61 |
| Ms. Renee D. Gala | President, CEO & Director | 53 |
| Mr. Philip L. Johnson | Executive VP & CFO | 61 |
| Ms. Neena M. Patil J.D. | Executive VP & Chief Legal Officer | 50 |
| Dr. Robert Iannone M.D. | Executive VP, Chief Medical Officer and Global Head of Research & Development | 58 |
| Ms. Samantha Pearce | Executive VP & Chief Commercial Officer | 59 |
| Ms. Patricia Carr | Senior VP & Chief Accounting Officer | 54 |
| Mr. John D. Bluth | Head of Investor Relations | 52 |
| Dr. Jed Black M.D. | Senior Vice President of Sleep & CNS Medicine | - |
| Mr. John Miller | Senior Vice President of Corporate Strategy | - |
Audit Risk
8
Board Risk
4
Compensation Risk
5
Shareholder Rights Risk
3
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Latest News
Recent headlines for JAZZ, sourced from Markets Gazette.
- 6/17/2026POSITIVEJazz Pharmaceuticals Gains Oncology Firepower Through AbCellera Collaboration
Jazz Pharmaceuticals has entered into a strategic collaboration with AbCellera to discover and develop novel cancer therapies. This partnership aims to leverage AbCellera's AI-powered antibody discovery platform to identify potential drug candidates for challenging oncology targets. Despite a recent setback in a Zepzelca trial, this move signals Jazz's commitment to strengthening its oncology pipeline. Analysts remain optimistic, maintaining positive price targets, suggesting that this collaboration could be a significant catalyst for future growth and value creation for shareholders.
via Markets Gazette